Landos Biopharma, Inc.
LABP · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $18 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $0 | $1 | $0 | $0 |
| Gross Profit | $0 | -$1 | $18 | -$0 |
| % Margin | – | – | 98.9% | – |
| R&D Expenses | $12 | $26 | $42 | $25 |
| G&A Expenses | $11 | $15 | $15 | $5 |
| SG&A Expenses | $11 | $15 | $15 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $1 | $0 | $0 |
| Operating Expenses | $23 | $41 | $57 | $31 |
| Operating Income | -$23 | -$41 | -$39 | -$31 |
| % Margin | – | – | -215.6% | – |
| Other Income/Exp. Net | $1 | $1 | $0 | $1 |
| Pre-Tax Income | -$22 | -$39 | -$38 | -$30 |
| Tax Expense | $0 | -$1 | -$0 | $0 |
| Net Income | -$22 | -$38 | -$38 | -$30 |
| % Margin | – | – | -212.4% | – |
| EPS | -3.5 | -9.44 | -9.5 | -7.51 |
| % Growth | 62.9% | 0.6% | -26.5% | – |
| EPS Diluted | -3.5 | -9.44 | -9.5 | -7.51 |
| Weighted Avg Shares Out | 6 | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 6 | 4 | 4 | 4 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $1 |
| EBITDA | -$23 | -$39 | -$39 | -$30 |
| % Margin | – | – | -214.6% | – |